Pharmacological agents, including pioglitazone and SGLT2 inhibitors, have shown potential in reducing hepatic steatosis and improving metabolic parameters, yet their long-term safety and efficacy in reversing fibrosis remain uncertain [46, 47]. This evidence concerns the gene SLC5A2 and fatty liver disease.